The route of priming influences the ability of respiratory virus-specific memory CD8+ T cells to be activated by residual antigen.
After respiratory virus infections, memory CD8+ T cells are maintained in the lung airways by a process of continual recruitment. Previous studies have suggested that this process is controlled, at least in the initial weeks after virus clearance, by residual antigen in the lung-draining mediastinal lymph nodes (MLNs). We used mouse models of influenza and parainfluenza virus infection to show that intranasally (i.n.) primed memory CD8+ T cells possess a unique ability to be reactivated by residual antigen in the MLN compared with intraperitoneally (i.p.) primed CD8+ T cells, resulting in the preferential recruitment of i.n.-primed memory CD8+ T cells to the lung airways. Furthermore, we demonstrate that the inability of i.p.-primed memory CD8+ T cells to access residual antigen can be corrected by a subsequent i.n. virus infection. Thus, two independent factors, initial CD8+ T cell priming in the MLN and prolonged presentation of residual antigen in the MLN, are required to maintain large numbers of antigen-specific memory CD8+ T cells in the lung airways.
Takamura
Shiki
S
Trudeau Institute, Saranac Lake, NY 12983, USA. stakamura@immunol.med.kindai.ac.jp
Roberts
Alan D
AD
Jelley-Gibbs
Dawn M
DM
Wittmer
Susan T
ST
Kohlmeier
Jacob E
JE
Woodland
David L
DL
D000281:Administration, Intranasal; D000818:Animals; D000956:Antigens, Viral / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000821:virology*; D002465:Cell Movement; D045142:Cross-Priming / Q000276:immunology*; D000939:Epitopes; D007156:Immunologic Memory / Q000276:immunology*; D007274:Injections, Intraperitoneal; D008168:Lung / Q000276:immunology* / Q000821:virology; D008198:Lymph Nodes / Q000276:immunology / Q000821:virology; D008482:Mediastinum / Q000821:virology; D051379:Mice; D009975:Orthomyxoviridae / Q000276:immunology*; D029082:Sendai virus / Q000276:immunology*; D013045:Species Specificity
D000956:Antigens, Viral; D000939:Epitopes
J Exp Med. 2001 Apr 16;193(8):981-6
11304559
Immunity. 2004 Feb;20(2):167-79
14975239
Nat Med. 2009 Mar;15(3):293-9
19219024
Immunity. 2003 Feb;18(2):265-77
12594953
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9716-23
8790397
J Immunol. 1994 Feb 15;152(4):1653-61
8120375
J Exp Med. 2007 Jul 9;204(7):1625-36
17606632
J Immunol. 2006 Jan 1;176(1):537-43
16365448
J Immunol. 2001 Sep 15;167(6):3293-9
11544317
Immunity. 2006 Sep;25(3):511-20
16973385
Annu Rev Immunol. 2009;27:61-82
18954284
Trends Immunol. 2005 May;26(5):242-7
15866236
Immunity. 2008 Jul 18;29(1):101-13
18617426
J Immunol. 2006 Feb 15;176(4):2161-72
16455972
Nat Immunol. 2007 Mar;8(3):285-93
17259988
J Immunol. 2005 Oct 1;175(7):4686-96
16177116
J Immunol. 2004 Apr 15;172(8):4875-82
15067066
Nat Immunol. 2005 Jul;6(7):698-706
15937486
Nat Rev Immunol. 2009 Mar;9(3):153-61
19240755
J Exp Med. 2005 Nov 21;202(10):1433-42
16301748
Lab Anim. 1992 Jul;26(3):200-5
1501434
J Immunol. 2007 Jul 1;179(1):36-40
17579018
Eur J Immunol. 2001 Sep;31(9):2574-82
11536155
Immunity. 2004 Oct;21(4):527-38
15485630
J Immunol. 2005 Oct 1;175(7):4677-85
16177115
J Immunol. 2001 Feb 1;166(3):1813-22
11160228
J Immunol. 2007 Apr 15;178(8):4721-5
17404250
Nature. 2003 Jul 3;424(6944):88-93
12840763
J Immunol. 2007 Jan 15;178(2):652-6
17202324
Immunity. 2004 May;20(5):551-62
15142524
Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8670-5
15163797
Immunity. 2006 Apr;24(4):439-49
16618602